Arkolith/Insider Trading/CNTA/Form 4

De Rubertis Francesco

DirectorCentessa Pharmaceuticals plc (CNTA) · full profile →Form 4 · filed Jun 24, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
6 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 24, 2026Disposed to issuer(D)4.4M——0
Jun 24, 2026Disposed to issuer(D)56K——0
Jun 24, 2026Disposed to issuer(D)3.9M——0
Jun 24, 2026Disposed to issuer(D)94K——0
Jun 24, 2026Disposed to issuer(D)11.2M——0
Jun 24, 2026Disposed to issuer(D)281K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001470831-26-000615) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML